

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1634

Kudaravalli, Sridhar et al.

Examiner: Pohnert, Steven C

INTERNATIONAL APPLICATION NO: PCT/EP03/10798

FILED: September 29, 2003

U.S. APPLICATION NO: 10/529613

35 USC §371 DATE: June 08, 2005

FOR: Methods for Predict Cholesterol Elevations during
Immunosuppressant Therapy

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed February 27, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

A concise explanation of the Japanese foreign language document may be found in the accompanying translation of the summary found on page 164*

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9308

Date: 7/17/16

Respectfully submitted,



Leslie Fischer
Attorney for Applicant
Reg. No. 58,393